In the coming years, clinical trial results for gilteritinib, IDH inhibitors, oral azacitidine, azacitidine and venetoclax, panobinostat, and various cellular therapy approaches are expected to greatly improve our understanding of the role of maintenance therapy for AML after allo-HCT. The gene discussed is IDH2; the disease is acute myeloid leukemia.